We aim to improve and accelerate sustainable and equitable access to quality medicines, vaccines and healthcare for underserved populations in places where we can have the greatest impact. For more information, see our Access to Healthcare page.
We apply evidence-based analyses and approaches to identify priority diseases areas and targeting regions and countries where actions is most urgently required. This effort is part of our business and fully embedded in our operations and decision-making processes, for sustainable impact.
Comprehensive Care Programs for Global Health Priority Diseases
We are focused on diseases considered as global health problems, especially those worsened by environmental challenges, such as respiratory diseases and diabetes, with the design of comprehensive access to care programs that include:
- Awareness and Education: Raising awareness and educating communities about health risks and disease prevention.
- Healthcare Capability Building: Training healthcare practitioners and caregivers to enhance healthcare capabilities.
- Policy strengthening: Collaborating with health authorities to strengthen policies for better disease diagnosis and management.
- Affordable Solutions: Providing affordable healthcare solutions at an adapted price where appropriate.
We concentrate our efforts on regions with the highest disease burden, unmet needs according to several criteria, and strong political commitment to tackle these diseases. We also consider the feasibility of implementing such programs to deliver the greatest sustainable impact. Sustainable and equitable access to care is a shared responsibility involving diverse stakeholders, including health authorities, policymakers, payers, care providers, and global organizations. By finding solutions along the patient care pathway and adapting different access models, we ensure we meet the specific needs of healthcare systems and local populations.
AccesS Diabetes
As part of Sanofi long-standing commitment to ensure sustainable and equitable access to Diabetes care for underserved population in all geographies, we are working with the governments in several low- and middle-income countries, such as Ghana, Nigeria, and South Africa. The “AccesS Diabetes” initiative co created with global/local actors spans across crucial aspects of the patient journey, including awareness and screening capacity; patient support initiatives, healthcare practitioner training, and provision of analogue insulins at an adapted price. As of Q1 2025, over 500 healthcare professionals and general practitioners (GPs) have been trained, increasing by 24 times the number of professionals managing diabetes and over 116,000 patients have been reached with Sanofi insulins via this initiative. This is complementary to what is done for access to diabetes care in the Low-Income Countries through the Global Health Unit.
Access to Insulin in the United States
In high-income countries like the U.S., Sanofi is also making insulin more affordable. The company has reduced the list price of Lantus® by 78% and set a $35 cap on out-of-pocket costs for insured patients, starting January 2024. Additionally, the price of Apidra® has been cut by 70%. Sanofi also supports uninsured patients through the Insulins ValYouSavings Program, providing insulin at $35 per 30-day supply. As a whole, the ValYouSavings program dedicated to vulnerable populations reach around 110,000 patients every year. For those facing financial difficulties, Sanofi offers free medications and ensures that insulin costs are capped under Medicare’s coverage. These measures reflect Sanofi's dedication to improving access to diabetes care worldwide.
Other Key Diabetes Access to Healthcare Programs
Our Kids and Diabetes in School program for diabetes prevention and education at school, in partnership with the International Diabetes Federation is, as of Q1 2025, rolled out in more than 20 countries, reaching over 690,000 children and 27,000 teachers since its launch in 2013.
In India, the Medical Mobile Units for diabetes and cardiovascular prevention and diagnosis allow to reach 500,000 beneficiaries in around 500 villages.
Eradicate Polio
Polio is a contagious disease mainly affecting children under five, with one in 200 infections leading to irreversible paralysis. Over the last 30 years, under the Global Polio Eradication Initiative (GPEI), 2.5 billion children have been immunized, reducing cases by 99% worldwide. By the end of 2024, polio was endemic in only Afghanistan and Pakistan with 93 wild polio virus cases reported compared with 12 in 2023. As a result, global efforts have saved nearly 20 million people from paralysis.
Polio eradication aims to permanently stop poliovirus transmission and eliminate poliomyelitis by 2026. Since 1988, Sanofi has been a key GPEI partner, supplying over 14 billion doses of Oral Polio Vaccine (OPV) and 1.5 billion doses of Inactivated Polio Vaccine (IPV) in the world. In 2024, Sanofi provided 33 million IPV doses to UNICEF for GAVI (Global Alliance for Vaccines and Immunization) countries and 30 million doses to Brazil, India, Indonesia, and the Philippines. Sanofi has expanded IPV production to meet global vaccination demands, supplying 460 million IPV doses to UNICEF between 2014 and 2024.
Global Health Unit (GHU)
Our pioneering, not-for-profit and sustainable business model provides access to a broad portfolio of Sanofi quality medicines across several therapeutic areas in 40 countries with the greatest unmet medical needs while funding local support programs and innovative entrepreneurial companies.
By 2030, the GHU aims to care for two million people with non-communicable diseases (NCDs). At the end of 2024, and since its launch in 2021, the GHU has reached over 790,000 patients with NCD treatment.
Local Healthcare System Strengthening
The GHU collaborates with local communities, Health authorities and NGOs to build sustainable healthcare systems for those who suffer from chronic diseases and require complex care, focusing on supply chain strengthening, medical training, and patient services.
At end of 2024, the GHU has co-designed more than 100 NCD programs and reached over 2.3 million beneficiaries and 18,000 Healthcare providers.
Impact Fund
Our Impact Investment Fund helps startups and innovators deliver scalable, sustainable healthcare solutions in underserved regions. With €25 million in funding, the Impact Investment Fund provides inclusive financing and technical assistance to small businesses, leveraging global, regional, and local investment to support improved access to medicines and healthcare at the last mile. In 2024, the fund made significant strides, completing three new investments, bringing the total to seven companies and over $9.6 million deployed. These investments focus on innovative solutions aimed at addressing critical healthcare challenges in hard-to-reach communities.
Rare Disease Treatment for Those Without Access
In certain circumstances, such as for certain rare diseases like lysosomal storage diseases and hemophilia, we develop humanitarian aid programs that provide access to free treatments for patients who meet the program’s criteria and otherwise would not have access to such treatments. Sanofi is committed to helping 1,000 patients with rare diseases who have no access to treatments and will donate 100,000 vials of medicine annually. In 2024, 121,130 vials were shipped, treating over 1,250 patients. The programme reaches patients in 72 countries. Cumulatively, it has supported more than 3,850 patients with six types of lysosomal storage disorder in more than 110 countries, continuing our 30+-year commitment to patients suffering from rare diseases, such as Fabry, Gaucher or Pompe diseases. 150 patients have been receiving free therapy for 20 years or longer through the program.
Relevant Links and Disclosures
Sanofi's approach to pricing reflects our continued efforts to support patient access while minimizing our impact on healthcare cost inflation. Our Global Access and Pricing Principles provide a framework founded on two pillars:
- Clear rationale for pricing and access at the time of launch of a new medicine or vaccine
- Inclusion of affordability criteria into pricing considerations for new launches